S-Adenosylmethionine (SAMe) Simply Explained

1. What It Is About

S-Adenosylmethionine, abbreviated SAMe, is not a plant substance. The body produces it itself. SAMe belongs to the substances that attach small building blocks to other molecules. These building blocks are called methyl groups; the process is called methylation. Thus SAMe participates in many processes in the body, including switches that help determine which genetic traits are read.

This is precisely what makes SAMe interesting for research. The most frequently cited works on the topic are nevertheless basic laboratory studies. They examine how SAMe acts in metabolism, not how it helps people. Fewer than thirty controlled studies exist in humans. It is striking that most of them address depressive complaints, although SAMe is also investigated in other areas.

SAMe is also offered as a food supplement. How much of it reaches the body depends on the formulation. A study in healthy people shows that different preparations cannot readily be substituted for one another 7.

2. What Studies Show

SAMe is best studied in depressive complaints. A large review summarised 23 studies with a total of 2183 participants 1. Compared with placebo, that is, a sham treatment, SAMe performed better. When SAMe was given in addition to an antidepressant, no clear difference was detectable. Direct comparison with antidepressants likewise showed none.

A second review of 14 studies and 1522 participants found, by contrast, no clear difference in any of the comparisons 6. The two reviews therefore reach differing conclusions. For the comparison with placebo there are thus indications, yet the question remains open.

Individual studies paint a similarly mixed picture. In a twelve-week study with 189 adults, SAMe was tested against placebo and against an antidepressant 4. Among the men in the study, 51 persons, SAMe was superior to placebo. Among the women, 62 persons, no clear change appeared. This gender-stratified analysis was performed retrospectively on existing data and requires independent replication.

In an eight-week study with 49 people with depression, complaints decreased markedly in all groups 10. The difference between SAMe and placebo was not distinct. A further study with 80 people combined SAMe with two probiotic strains 9. Scores on two mood questionnaires decreased markedly. Because both components were given together, the change cannot be attributed to SAMe alone.

For the liver, a review of two placebo-controlled studies reports that one liver parameter in blood fell markedly under SAMe within two weeks 2.

In Alzheimer’s disease, a study with 63 persons over 180 days examined whether a protein in blood linked to the condition changed 8. No difference between the groups appeared. SAMe was well tolerated during this period.

A review of mood, behaviour and sleep screened 1881 papers and included 36 11. In 24 of these 36 studies SAMe was effective. Regarding memory and cognition, a review collated animal and human studies and found no clear differences overall 3.

3. What Remains Unclear

The two large reviews on depression contradict each other, and the precise reasons remain open. The observation that SAMe acts differently in men than in women derives from a retrospective analysis and requires independent replication. In a study with 31 adults with traumatic experiences, additional SAMe did not alter the participants’ own blood levels 5, although measurable shifts in traces on the genetic material occurred. Whether this produces a benefit is an open question.

How SAMe and related substances are measured in blood is not yet standardised across laboratories 12. Follow-up observations beyond the mostly short treatment periods are rare. For fatigue, joints and bones, and for viral infections, a dedicated, precisely evaluable trial is still outstanding.

4. What This Means in Everyday Life

SAMe is a substance the body produces itself and at the same time a preparation sold as a food supplement. Research on it is unusually divided: many studies examine the substance in humans, comparatively few examine it in the laboratory. Where humans were studied, the focus was predominantly on depressive complaints.

Readers of the study situation should keep two things separate. That SAMe participates in methylations in the body is well described. Whether an additional dose actually helps people in a particular area is not thereby answered. Results on mood diverge, and for memory, liver and other areas the questions remain open.

The next step would be to clarify which group of people, which treatment duration and which amount actually show an advantage in a large, independent study.

All details with study numbers and sources: detailed page on S-Adenosylmethionine (SAMe). For children: S-Adenosylmethionine (SAMe) for children.